Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.
BCMA-Directed Bispecifics in Relapsed/Refractory Multiple Myeloma
Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.
Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
Families of Children With ALL Face Extreme Financial Toxicity
3
Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib
4
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
5
